Back to today’s briefing

Story perspectives

U.S. Reconsiders Moderna's Bird Flu Vaccine Amid Crisis

3/1/2025

38 8

Summary

Story summary

U.S. health officials are reassessing a $590 million deal with Moderna for a bird flu vaccine, hinting at a possible departure from mRNA technology. This decision arises during a severe bird flu outbreak that has skyrocketed egg prices by nearly 160% since January 2021, prompting the Trump administration to implement a five-point plan to tackle the crisis.

1 of 1

Story summary

U.S. health officials are reassessing a $590 million deal with Moderna for a bird flu vaccine, hinting at a possible departure from mRNA technology. This decision arises during a severe bird flu outbreak that has skyrocketed egg prices by nearly 160% since January 2021, prompting the Trump administration to implement a five-point plan to tackle the crisis.